FDA Approves CAPVAXIVE, Sixth Product Using Pfenex Expression Technology; Ligand Pharmaceuticals Entitled To Royalties On Global Sales
FDA Approves CAPVAXIVE, Sixth Product Using Pfenex Expression Technology; Ligand Pharmaceuticals Entitled To Royalties On Global Sales
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.